Vitality Biopharma, Inc. Introduces Cannabinoid Pharmaceutical VITA-100 as Prodrug of THC
January 03, 2018 at 07:00 pm IST
Share
Vitality Biopharma, Inc. introduced its lead cannabinoid drug formulation VITA-100 as a non-psychoactive prodrug of THC. Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which enable targeted delivery of THC to the large intestine. THC has been previously reviewed and approved by the U.S. Food & Drug Administration (FDA) under the name dronabinol, and has been established as safe and effective for use with appetite stimulation and for treatment of nausea and vomiting. Vitality’s cannabosides could enable oral delivery of large concentrations of cannabinoids in order to provide therapeutic benefits while reducing or eliminating psychoactivity by limiting entry of THC into the bloodstream or brain. Vitality is focusing initial clinical development efforts on VITA-100, a proprietary THC cannabinoid drug formulation, and plans to complete a first-in-man clinical study in the first half of 2018. The treatment indications the Company plans to evaluate in Phase 2 trials include inflammatory bowel disease (IBD), irritable bowel syndrome, and narcotic bowel syndrome, a severe form of opiate-induced abdominal pain. Independent clinical trial results suggest that THC can help induce remission in drug-resistant Crohn’s disease and that the vast majority (75% or more) of IBD patients report improvement in visceral pain and abdominal cramping with cannabinoid treatment. More than 1.4 million Americans have been diagnosed with IBD, which includes Crohn’s disease and ulcerative colitis. Most IBD patients are diagnosed before age 30 and require life-long treatment.
Range Impact, Inc. is focused on improving the health and wellness of people and the planet through innovative approach to impact investing. It owns and operates various complementary operating businesses focused on developing long-term solutions to environmental, social and health challenges, with a particular focus on acquiring, reclaiming and repurposing mine sites and other undervalued land. Its segments include Range Reclaim, Range Water, Range Security, Drug Development and Range Land. Range Reclaim segment provides land reclamation, water restoration and environmental consulting services to mining and non-mining companies throughout Appalachia. Range Water segment operates biochar product development and water solutions business. Range Security segment offers security services on mine land being reclaimed and repurposed for non-fossil fuel uses. Range Land is focused on acquiring former mine lands with the goal of reclaiming and repurposing the sites for non-fossil fuel uses.